Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap’s research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap’s lead drug compound, PhGalpha1, is in preclinical development and targets PKC alpha. The Company has a pipeline of compounds in the design stage which are selective inhibitors of other isoforms of PKC. The Company’s strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. ( www.pharmagap.com )
PharmaGap Inc.
100 Sussex Drive
Ottawa, Ontario K1A 0R6
Canada
Tel: (613) 998-3400
Fax: (613) 998-3399